Spero Therapeutics, Inc. (SPRO) News
Filter SPRO News Items
SPRO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SPRO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest SPRO News From Around the Web
Below are the latest news stories about SPERO THERAPEUTICS INC that investors may wish to consider to help them evaluate SPRO as an investment opportunity.
Spero Therapeutics Provides Business Update and Announces Interim Leadership ChangesEsther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company’s Response to a Wells Notice from the SEC Relating to Certain Public Disclosures Made in 2022 Phase 3 PIVOT-PO Trial of Tebipenem HBr Reaches Over 60% Enrollment as of December 31, 2024; Remains on Track to Complete Enrollment in 2H 2025 Cash Balance and Cash Runway Guidance Remains into mid-2026 CAMBRIDGE, Mass., Jan. 10, 2025 (GL |
Here's Why Arcutis Stock More Than Doubled in Market Value in One YearThe rally in ARQT's stock could be attributed to the encouraging regulatory updates seeking label expansion for its sole marketed drug. |
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLACapricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States. |
Neumora Stock Hits Record Low on Depression Drug Study FailureNMRA stock falls after its experimental depression treatment failed to meet the primary and secondary endpoints in the first of three late-stage studies. |
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder StudyData from a mid-stage study show that treatment with Edgewise's experimental drug reduces levels of a biomarker related to skeletal muscle damage. |
Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerSpero Therapeutics (SPRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
Here's Why Q32 Bio Stock Hit a New Record Low on WednesdayShares of QTTB fall after its experimental autoimmune disease drug failed to meet the primary endpoint in a mid-stage study for eczema. |
JANX Stock Hits Record High on Prostate Cancer Study DataAn early-stage study data shows that treatment with Janux's JANX007 generates deep and durable efficacy responses in heavily pretreated patients with mCRPC. |
PTCT Stock Soars on Licensing Deal With NVS for Huntington's TherapyPer the terms, PTC will receive $1 billion in upfront payment from Novartis upon the deal's closure. It is also eligible for milestone payments of up to $1.9 billion. |
Grifols Stock Declines After Brookfield Drops Buyout OfferBrookfield decides to drop its buyout offer for GRFS following discrepancies over the company's valuation. |